BeOne Medicines (NASDAQ:ONC) Price Target Raised to $435.00

BeOne Medicines (NASDAQ:ONC) had its price objective raised by research analysts at Wells Fargo & Company from $400.00 to $435.00 in a report issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would indicate a potential upside of 6.83% from the stock’s previous close.

Several other research firms also recently weighed in on ONC. Citizens Jmp lifted their price target on shares of BeOne Medicines from $396.00 to $405.00 and gave the company a “market outperform” rating in a research note on Thursday, August 6th. TD Cowen raised their price objective on BeOne Medicines from $424.00 to $454.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Guggenheim lifted their target price on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating and issued a $370.00 target price on shares of BeOne Medicines in a report on Monday, August 10th. Finally, Barclays increased their price target on BeOne Medicines from $407.00 to $415.00 and gave the stock an “overweight” rating in a research report on Thursday, September 10th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $426.59.

BeOne Medicines Trading Up 5.1%

ONC traded up $19.94 on Friday, reaching $407.19. 189,636 shares of the company traded hands, compared to its average volume of 316,714. BeOne Medicines has a one year low of $253.95 and a one year high of $406.00. The firm has a fifty day simple moving average of $362.80 and a two-hundred day simple moving average of $325.98. The company has a market cap of $44.70 billion, a P/E ratio of 71.54 and a beta of 0.63. The company has a quick ratio of 3.06, a current ratio of 3.40 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.34 by $1.30. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.76 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. As a group, equities research analysts expect that BeOne Medicines will post 8.99 earnings per share for the current year.

Insider Buying and Selling at BeOne Medicines

In other news, insider Xiaodong Wang sold 38,287 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $349.10, for a total value of $13,365,991.70. Following the completion of the transaction, the insider directly owned 6,079 shares of the company’s stock, valued at approximately $2,122,178.90. The trade was a 86.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Oyler sold 115,011 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $357.87, for a total value of $41,158,986.57. Following the sale, the chief executive officer owned 125,799 shares of the company’s stock, valued at $45,019,688.13. This trade represents a 47.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 376,373 shares of company stock worth $134,848,154. 6.19% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in shares of BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after buying an additional 26,441 shares in the last quarter. Baird Financial Group Inc. raised its stake in shares of BeOne Medicines by 5.5% during the 2nd quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after acquiring an additional 19,327 shares in the last quarter. Candriam S.C.A. lifted its position in BeOne Medicines by 31.7% during the first quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after acquiring an additional 62,470 shares during the last quarter. First Trust Advisors LP lifted its position in BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in BeOne Medicines by 102.1% in the first quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after acquiring an additional 78,027 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

Key Stories Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: BeOne reported third-quarter EPS of $3.64, topping the $2.34 consensus estimate, while revenue of $1.89 billion exceeded expectations of $1.76 billion. The company also raised its 2026 revenue guidance, adding to the positive outlook. BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised
• Positive Sentiment: The FDA granted priority review to a BRUKINSA combination for first-line mantle cell lymphoma. The review could bring a decision on the potential label expansion sooner, creating an opportunity to broaden the treatment’s use if approved. FDA Priority Review for BRUKINSA Combination

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for cancer patients. Formerly known as BeiGene, the company operates an integrated biotechnology platform spanning research, clinical development, regulatory activities and commercial operations.

Its portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used in the treatment of several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy approved in multiple markets for certain cancers.